The only published RCT in this setting is the SORMAIN trial which randomized 83 patients with FLT3-ITD–positive AML in CR after alloSCT to 24 months of sorafenib (n = 43) or placebo (n = 40) (88). The gene discussed is FLT3; the disease is acute myeloid leukemia.